NO781786L - Terapeutisk middel. - Google Patents

Terapeutisk middel.

Info

Publication number
NO781786L
NO781786L NO78781786A NO781786A NO781786L NO 781786 L NO781786 L NO 781786L NO 78781786 A NO78781786 A NO 78781786A NO 781786 A NO781786 A NO 781786A NO 781786 L NO781786 L NO 781786L
Authority
NO
Norway
Prior art keywords
therapeutic medicine
therapeutic
medicine
Prior art date
Application number
NO78781786A
Other languages
English (en)
Other versions
NO150361C (no
NO150361B (no
Inventor
Peter Frederick Juby
Original Assignee
Bristol Myers Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Co filed Critical Bristol Myers Co
Publication of NO781786L publication Critical patent/NO781786L/no
Publication of NO150361B publication Critical patent/NO150361B/no
Publication of NO150361C publication Critical patent/NO150361C/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40Acylated substituent nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
NO781786A 1977-05-25 1978-05-23 Analogifremgangsmaate til fremstilling av terapeutisk aktive 3-(1h-tetrazol-5-yl)-4h-(pyrido-(1,2-a)-pyrimidin-4-on-derivater NO150361C (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/800,264 US4122274A (en) 1977-05-25 1977-05-25 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones

Publications (3)

Publication Number Publication Date
NO781786L true NO781786L (no) 1978-11-28
NO150361B NO150361B (no) 1984-06-25
NO150361C NO150361C (no) 1984-10-03

Family

ID=25177928

Family Applications (1)

Application Number Title Priority Date Filing Date
NO781786A NO150361C (no) 1977-05-25 1978-05-23 Analogifremgangsmaate til fremstilling av terapeutisk aktive 3-(1h-tetrazol-5-yl)-4h-(pyrido-(1,2-a)-pyrimidin-4-on-derivater

Country Status (26)

Country Link
US (1) US4122274A (no)
JP (1) JPS6050197B2 (no)
AT (1) AT365187B (no)
AU (1) AU521211B2 (no)
BE (1) BE867295A (no)
CA (1) CA1098520A (no)
CH (1) CH642656A5 (no)
CY (1) CY1218A (no)
DE (1) DE2822544A1 (no)
DK (1) DK160279C (no)
FI (1) FI64594C (no)
FR (1) FR2401159A1 (no)
GB (1) GB1596476A (no)
GR (1) GR71887B (no)
HK (1) HK25884A (no)
IE (1) IE46849B1 (no)
IT (1) IT1105040B (no)
KE (1) KE3357A (no)
LU (1) LU79694A1 (no)
MY (1) MY8500305A (no)
NL (1) NL190702C (no)
NO (1) NO150361C (no)
SE (1) SE437830B (no)
SG (1) SG73383G (no)
YU (2) YU42163B (no)
ZA (1) ZA782816B (no)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4495189A (en) * 1975-11-27 1985-01-22 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara R.T. Condensed pyrimidines
HU173438B (hu) * 1975-11-27 1979-05-28 Chinoin Gyogyszer Es Vegyeszet Sposob poluchenija novykh proizvodnykh 4-okso-1,6,7,8-/tetragidro-4h-pirido/1,2/pirimidina s zaderzhivajuhhejj vozgoranie aktivnot'ju i protivosvertivajuhhem effektom
HU180439B (en) * 1977-12-29 1983-03-28 Chinoin Gyogyszer Es Vegyeszet Process for producing 9-amino-pyrido-square bracket-1,2-a-square bracket closed-pyrimidine derivatives
US4192944A (en) * 1978-04-03 1980-03-11 Bristol-Myers Company Optionally substituted 4-oxo-4H-pyrido[1,2-a]pyrimidine-3-N-(1H-tetrazol-4-yl)carboxamides and their use as antiallergy agents
US4223031A (en) * 1978-05-05 1980-09-16 Mead Johnson & Company Azolopyrimidinones
US4491587A (en) * 1978-05-05 1985-01-01 Mead Johnson & Company Tetrazole derivatives
US4282360A (en) * 1979-10-12 1981-08-04 Hoffmann-La Roche Inc. 7-Methylthio or methylsulfinyl-5-oxo-5H-thiazolo[2,3-b]quinazoline-2-carboxylic acid
US4419357A (en) * 1982-01-18 1983-12-06 The Dow Chemical Company 3-(1H-Tetrazol-5-yl)-4(3H)-quinazolinones
US4474953A (en) * 1982-09-09 1984-10-02 Riker Laboratories, Inc. Process and intermediates for the preparation of 3(1H-tetrazol-5-yl)-4H-pyrido[1,2-a]pyrimidin-4-ones
US4476130A (en) * 1982-09-09 1984-10-09 Riker Laboratories, Inc. 3-(1H-Tetrazol-5-yl)-4H-pyrimido[2,1-b]benzoxazol-4-one compounds exhibiting anti-allergic activity
US4507477A (en) * 1982-09-09 1985-03-26 Riker Laboratories, Inc. Process for tetrazolyl-pyrimidinone derivatives
US4457932A (en) * 1983-07-22 1984-07-03 Bristol-Myers Company Anti-ulcer agents
DK169580B1 (da) * 1985-09-25 1994-12-12 Shionogi & Co 9-(substitueret thio)-4H-pyrido[1,2-a]pyrimidin-4-on-derivater, fremgangsmåde til fremstilling deraf samt farmaceutiske præparater indeholdende sådanne derivater
JPS63183581A (ja) * 1985-10-03 1988-07-28 Tokyo Tanabe Co Ltd ピリド〔1,2−a〕ピリミジン誘導体、その製造法及びそれを有効成分とするアレルギ−疾患治療薬
JPS62242682A (ja) * 1986-04-16 1987-10-23 Tokyo Tanabe Co Ltd 新規なピリド[1,2―a]ピリミジン誘導体及びその製造法
JP2504788B2 (ja) * 1987-11-10 1996-06-05 東京田辺製薬株式会社 9−メチル−3−(1H−テトラゾ―ル−5−イル)−4H−ピリド[1,2−a]ピリミジン−4−オンカリウム塩の水性製剤
WO1989006130A1 (en) * 1987-12-25 1989-07-13 Santen Pharmaceutical Co., Ltd. Antiallergic eye drop
CA2010336C (en) * 1989-02-27 1996-11-19 Atsunori Sano Process for producing pyrido[1,2-a]pyrimidine derivative
HU209793B (en) * 1990-09-25 1994-11-28 Chinoin Gyogyszer Es Vegyeszet Process for the production of pyrido[1,2-a]pyrimidine-derivatives and pharmaceutical compositions containing the same
EP0653209A4 (en) 1992-07-30 1997-03-19 Tokyo Tanabe Co MEDICINAL PRODUCTS FOR INFLAMMATORY COLON DISEASES.
US5527802A (en) * 1992-10-01 1996-06-18 Bristol-Myers Squibb Company New uses of 3-tetrazolo -5,6,7,8- substituted-pyrido (1,2-a) pyrimidin-4-ones
JPH0892093A (ja) * 1994-11-10 1996-04-09 Tokyo Tanabe Co Ltd 9−メチル−3−(1H−テトラゾール−5−イル)−4H−ピリド[1,2−a]ピリミジン−4−オンの水性製剤
KR100885007B1 (ko) * 2001-02-26 2009-02-20 미쓰비시 타나베 파마 코퍼레이션 신질환·신부전의 예방 또는 치료를 위한 약학 조성물
ITMI20011764A1 (it) * 2001-08-10 2003-02-10 Dinamite Dipharma Spa Metodo per l'ottenimento del pemirolast ad elevata purezza
GB0316546D0 (en) 2003-07-15 2003-08-20 Novartis Ag Process for the manufacture of organic compounds
CA2672976A1 (en) * 2006-12-18 2008-06-26 Cardoz Ab New combination for use in the treatment of inflammatory disorders
ATE543501T1 (de) * 2006-12-20 2012-02-15 Cardoz Ab Kombination von pemirolast und ramatroban zur verwendung bei der behandlung von entzündlichen erkrankungen
AU2008273997A1 (en) * 2007-07-11 2009-01-15 Cardoz Ab Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a PPAR gamma agonist
WO2009007675A2 (en) * 2007-07-11 2009-01-15 Cardoz Ab Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a p2 gamma 12 antagonist
WO2009007679A2 (en) * 2007-07-11 2009-01-15 Cardoz Ab Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a thromboxane a2 antagonist
US20110092463A1 (en) * 2008-04-07 2011-04-21 Johan Raud Combination for use in the treatment of inflammatory disorders
EP3141549A1 (en) * 2009-06-16 2017-03-15 RSPR Pharma AB Crystalline form of pemirolast for use in the treatment of inflammations
USD661900S1 (en) 2010-02-22 2012-06-19 Bajer Design & Marketing, Inc. Collapsible structure
WO2013119916A2 (en) 2012-02-10 2013-08-15 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
CN104302181B (zh) 2012-03-01 2017-09-15 Ptc医疗公司 用于治疗脊髓性肌萎缩的化合物
CN104470909B (zh) 2012-03-23 2018-04-24 Ptc医疗公司 用于治疗脊髓性肌萎缩的化合物
WO2015105657A1 (en) 2013-12-19 2015-07-16 Ptc Therapeutics, Inc. Methods for modulating the amount of rna transcripts
US20160243122A1 (en) 2014-10-23 2016-08-25 Rspr Pharma Ab Use of pemirolast in the treatment of acute asthma
WO2016102941A1 (en) 2014-12-22 2016-06-30 Rspr Pharma Ab New combination of pemirolast and montelukast
EP3298017B1 (en) * 2015-05-20 2019-08-14 H. Hoffnabb-La Roche Ag Compounds for treating spinal muscular atrophy
WO2016196386A1 (en) 2015-05-30 2016-12-08 Ptc Therapeutics, Inc. Methods for modulating rna splicing
GB201518831D0 (en) 2015-10-23 2015-12-09 Rspr Pharma Ab New use
CN113717154A (zh) 2015-12-10 2021-11-30 Ptc医疗公司 用于治疗亨廷顿病的方法
GB201601138D0 (en) * 2016-01-21 2016-03-09 Rspr Pharma Ab New use
US11702646B2 (en) 2016-11-28 2023-07-18 Ptc Therapeutics, Inc. Methods for modulating RNA splicing
WO2018226622A1 (en) 2017-06-05 2018-12-13 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
CN111372611A (zh) 2017-06-14 2020-07-03 Ptc医疗公司 修饰rna剪接的方法
EP3645121A4 (en) 2017-06-28 2021-03-17 PTC Therapeutics, Inc. HUNTINGTON'S DISEASE TREATMENT METHODS
BR112019027717A2 (pt) 2017-06-28 2020-07-28 Ptc Therapeutics, Inc. métodos para tratar a doença de huntington
KR20210005559A (ko) 2018-03-27 2021-01-14 피티씨 테라퓨틱스, 인크. 헌팅턴병 치료 화합물
CA3103976A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heterocyclic and heteroaryl compounds for treating huntington's disease
WO2020005882A1 (en) 2018-06-27 2020-01-02 Ptc Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3072485A (en) * 1960-08-24 1963-01-08 Eastman Kodak Co Optically sensitized azido polymers for photomechanical resist compositions
CH538494A (de) * 1966-11-02 1973-06-30 Chinoin Gyogyszer Es Vegyeszet Verfahren zur Herstellung neuer Homopyrimidazol-Derivate
US3960847A (en) * 1972-04-17 1976-06-01 E. R. Squibb & Sons, Inc. 9-Substituted-4-oxopyrido(1,2-α)pyrimidine-3-carboxylic acids and derivatives thereof
US3929787A (en) * 1974-04-22 1975-12-30 Squibb & Sons Inc 6,7,8,9-Tetrahydro-pyrido(1,2-a)pyrimidin-4-ones
US3960863A (en) * 1974-06-25 1976-06-01 Sankyo Company Limited Pyrido[1,2-a]pyrimidinone derivatives
US4017625A (en) * 1975-08-01 1977-04-12 Pfizer Inc. Anti-allergic N-(5-tetrazolyl)-1-oxo-1H-6-alkoxypyrimido-[1,2-a]quinoline-2-carboxamides and intermediates therefor
US4012387A (en) * 1975-09-18 1977-03-15 Warner-Lambert Company Benzo-[g]pyrido[2,1-b]quinazolinones

Also Published As

Publication number Publication date
SE437830B (sv) 1985-03-18
CH642656A5 (de) 1984-04-30
MY8500305A (en) 1985-12-31
YU123678A (en) 1983-02-28
HK25884A (en) 1984-03-30
NL7805534A (nl) 1978-11-28
NO150361C (no) 1984-10-03
US4122274A (en) 1978-10-24
IT7849523A0 (it) 1978-05-24
YU233082A (en) 1988-08-31
GR71887B (no) 1983-08-04
GB1596476A (en) 1981-08-26
FI781614A (fi) 1978-11-26
DK160279C (da) 1991-07-22
KE3357A (en) 1984-02-03
IT1105040B (it) 1985-10-28
IE46849B1 (en) 1983-10-05
AU521211B2 (en) 1982-03-25
SE7805954L (sv) 1978-11-26
DK160279B (da) 1991-02-18
FR2401159A1 (fr) 1979-03-23
NL190702B (nl) 1994-02-01
JPS6050197B2 (ja) 1985-11-07
DE2822544C2 (no) 1988-10-27
DK228878A (da) 1978-11-26
ZA782816B (en) 1979-05-30
AT365187B (de) 1981-12-28
CY1218A (en) 1984-04-06
FR2401159B1 (no) 1983-05-20
JPS5436294A (en) 1979-03-16
CA1098520A (en) 1981-03-31
LU79694A1 (fr) 1979-02-02
YU42163B (en) 1988-06-30
NL190702C (nl) 1994-07-01
YU44212B (en) 1990-04-30
AU3631978A (en) 1979-11-29
IE781036L (en) 1978-11-25
BE867295A (fr) 1978-11-20
DE2822544A1 (de) 1978-12-07
ATA373278A (de) 1981-05-15
FI64594C (fi) 1983-12-12
SG73383G (en) 1984-08-03
FI64594B (fi) 1983-08-31
NO150361B (no) 1984-06-25

Similar Documents

Publication Publication Date Title
NO781786L (no) Terapeutisk middel.
NL7801187A (nl) Farmaceutisch tablet.
IT7831065A0 (it) Siringa.
NL7711426A (nl) Injectiespuit.
SE7803527L (sv) Lekemedelsdosenhet
FI781613A (fi) Terapeutiska hydantoinfoereningar
NL7804481A (nl) Catheter.
NL7607310A (nl) Wegwerpluier.
NL7810051A (nl) Catheter.
NL7608447A (nl) Wegwerpluier.
NL7802592A (nl) Elektrode-katheter.
NL7611905A (nl) Wegwerpinjektiespuit.
NL7611074A (nl) Wegwerpluier.
NL7614482A (nl) Wegwerpluier.
DK148408C (da) Medicinsk klaebemiddel
NL7805717A (nl) Polypeptiden met geneeskundige activiteit.
NL7612890A (nl) Wegwerpbare injectiespuit.
NL7711446A (nl) Pharmaceutische desinfecterend preparaat.
NL7801765A (nl) Ziekenhuisbed.
NL7714414A (nl) Catheter.
NL7612183A (nl) Wegwerpluier.
NL7809626A (nl) Therapeutische preparaat.
NL7801921A (nl) Farmaceutische preparaten.
NL7612476A (nl) Wegwerpluier.
NL7808864A (nl) Injectiespuit.